<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717442</url>
  </required_header>
  <id_info>
    <org_study_id>104-201508</org_study_id>
    <nct_id>NCT02717442</nct_id>
  </id_info>
  <brief_title>Study of OTO-104 in Subjects With Unilateral Meniere's Disease</brief_title>
  <acronym>AVERTS-2</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of
      Meniere's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in number of definitive vertigo days compared to placebo as assessed by a daily diary</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hearing from baseline as assessed by audiometry</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the condition of the ear from baseline as assessed by otoscopic examinations</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events as a measure of safety and tolerability</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of vertigo experience on daily activities</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Meniere's Disease</condition>
  <arm_group>
    <arm_group_label>OTO-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-104</intervention_name>
    <description>Single intratympanic injection of 12 mg OTO-104</description>
    <arm_group_label>OTO-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intratympanic injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes, but is not limited to:

          -  Subject is a male or female aged 18 to 85 years, inclusive.

          -  Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAO-HNS
             criteria.

          -  Subject self-reports active, definitive vertigo episodes for the 2 months prior to
             the study lead-in period.

        Exclusion Criteria includes, but is not limited to:

          -  Subject is pregnant or lactating.

          -  Subject has a history of immunodeficiency disease.

          -  Subject has previously been randomized to a trial of OTO-104.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl LeBel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Otonomy, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gemma Groppi</last_name>
    <phone>0800 0868 525</phone>
    <email>menieresdiseasestudy@cssienroll.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Many sites in Europe. Refer to the contact info listed below.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>menieresdiseasestudy@cssienroll.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>March 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meniere's Disease</keyword>
  <keyword>Vertigo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
